Investment Analysis Report: XAIR (en)

This report is auto-generated by an educational research tool for learning purposes only. The content is for general information and educational reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. **# [Qiltrack AI] Beyond Air Inc (XAIR) 3-Minute Overview** --- ### 1. 30-Second Snapshot **One-liner:** Beyond Air is a tiny, high‑risk medtech/biopharma play trying to commercialize nitric oxide (NO)–based devices and therapies, still very much in “burn cash, prove it works, then scale” mode. **Basic profile** - Market cap: **~$7.5m** (micro-cap) - Sector: **Health Care (medical device/biopharma)** - Exchange: **NASDAQ** - Share price: **$2.15** (up ~145% today) - 52-week range: **$0.67 – $10.40** --- #### The 3 things you really should know 1. **Deeply loss-making, tiny revenue base** Margins are extreme: gross margin **-6.7%**, operating margin **-607%**, net margin **-633%**, ROE **-272%**. That usually means: very small revenue, heavy R&D and SG&A, and the business is still in “funded experiment” phase rather than a mature commercial operation. Survival depends on access to capital, not profits. 2. **Growth is there, but from a low and volatile base** 3‑year revenue growth is a strong **+62%**, but 5‑year growth is actually **-13.7%**. So revenue is recovering from earlier declines rather than compounding smoothly. Losses per share are shrinking (EPS from about **-3.00** to **-1.25** over the last 4 quarters), but still very large. 3. **Speculative valuation, near the low end of its 52‑week range** No meaningful P/E (still loss-making). Price-to-sales is **~1.3x** and price-to-book **~1.8x**, which is not crazy for an early‑stage medtech—but the market cap is only ~$7.5m and the stock sits around **15%** of its 52‑week range. That combination usually means: the market is very sceptical about execution and financing risk, but any good news can move the stock violently (as today’s +145% move shows). --- #### Quick Health Check | Dimension | Rating | Detail | |------------------|--------------|--------| | Profitability | Weak | Net margin **-633%**, ROE **-272%** – heavy cash burner, nowhere near breakeven. | | Growth pace | Mixed | 3Y revenue growth **+62%**, but 5Y **-14%** – rebound, not steady growth. | | Financial health | OK (for now) | Current ratio **4.24** and quick ratio **1.60** – short‑term liquidity is decent, but cash flow per share **-2.15** shows ongoing burn. | | Valuation | Speculative | No P/E, P/S **1.29x**, P/B **1.77x** and price near 52‑week lows – market is pricing in high risk and potential dilution. | --- ### 2. Two-Minute Walkthrough #### How does this company actually make money? **Business model in one sentence:** Develop and commercialize nitric oxide (NO)–based medical devices and biopharmaceutical therapies, getting paid by hospitals/clinics (devices) and potentially payers (if drug indications succeed). **Revenue mix:** The data you provided doesn’t break out revenue by segment, but based on the description: | Segment (inferred) | Share | Trend | Comment | |-----------------------------------------|-------|-------|---------| | NO-based medical devices (commercial) | n/a | Up | Company is “commercial stage”; likely still very small but growing from a low base. | | NO-based biopharma / pipeline programs | n/a | n/a | Primarily pre-commercial R&D; cost center today, optionality for the future. | *(Exact percentages by segment are not provided.)* **Earning efficiency:** | Metric | Value | Level | What it means | |----------------------|-----------:|----------------|---------------| | Gross margin (TTM) | **-6.7%** | Very weak | Either low pricing power or early-stage scaling issues; may still be ramping initial products. | | Operating margin | **-607%** | Extremely weak | Opex dwarfs revenue; typical for a very early commercial biotech/medtech. | | Net profit margin | **-633%** | Extremely weak | Financing and below‑the‑line items add to losses. | | ROE (TTM) | **-272%** | Very poor | Equity base is small relative to losses; not sustainable without fresh capital. | Bottom line: right now it’s a **R&D + commercialization ramp story**, not a “profitable business” story. --- #### How is growth? **Growth profile:** Call it **“early-stage rebound with big losses”**. We don’t have detailed year-by-year revenue, but: - **3Y revenue growth:** **+62%** – strong. - **5Y revenue growth:** **-13.7%** – suggests there was a big dip earlier; recovery is recent. **Profit growth (EPS):** From the last four reported quarters (EPS, all negative): | Quarter (FY end) | EPS actual | EPS vs prior quarters (direction) | |------------------|-----------:|-----------------------------------| | 2024-12-31 | -3.00 | Starting from a deep loss base. | | 2025-03-31 | -1.80 | Loss narrowing. | | 2025-06-30 | -1.53 | Loss narrowing further. | | 2025-09-30 | -1.25 | Loss still narrowing. | So **losses are shrinking**, which is good, but they’re still very large per share. **Growth quality:** From what we can see: - Growth appears **organic** (no M&A data provided). - Profitability is far behind revenue growth – the company is clearly prioritizing pipeline and commercialization investment over near‑term profits. - Because gross margin is still slightly negative, even “growing faster” doesn’t translate into operating leverage yet. This is **not** a “high-quality compounding” story; it’s a **binary-ish development/commercial success** story. --- #### Is the balance sheet OK? **In one line:** Short-term liquidity looks fine, leverage is modest, but the business **relies on external funding** unless losses narrow dramatically. | Metric | Value | Reference | Assessment | |---------------------------|---------:|-----------------|------------| | Debt-to-equity (annual) | **0.72** | <1 often OK | Moderate leverage; not over‑indebted. | | Long-term D/E | **0.68** | | Most debt is long term; not too bad structurally. | | Current ratio (quarterly)| **4.24** | >1.5 good | Plenty of current assets vs current liabilities. | | Quick ratio (annual) | **1.60** | >1.0 OK | After inventory, still reasonable liquidity. | | Interest coverage | **-47.3**| >2 healthy | EBIT is deeply negative; interest only sustainable via new capital, not operations. | | Cash flow per share (TTM)| **-2.15**| >0 preferred | Burning cash; no free cash flow support yet. | So: **balance sheet isn’t “about to collapse”**, but it’s **not self-funding**. Equity raises, debt, or partnerships are likely needed if commercialization doesn’t scale fast. --- #### Is the stock cheap or expensive? **52-week positioning:** - 52-week low: **$0.67** - 52-week high: **$10.40** - Current: **$2.15** Position in range ≈ **15% from the low** → closer to the **low-end** of the year’s range, even after a huge +145% move today. | Range segment | Cheap zone | Fair zone | Expensive zone | |--------------|-----------:|----------:|---------------:| | Definition | 0–33% | 33–66% | 66–100% | | Current pos. | ● (≈15%) | | | **Valuation multiples:** | Lens | Current | Comparison | Takeaway | |-------------------|--------:|-----------|----------| | P/E (TTM) | n/a | n/a | Loss-making → P/E not meaningful. | | P/Sales (TTM) | **1.29x** | No peer data provided | Reasonable for early-stage, but reflects risk and tiny scale. | | P/Book (annual) | **1.77x** | No peer data provided | Slight premium to book; not “bubble” territory. | **What is the valuation really “pricing in”?** - The micro-cap size and low multiples **signal low market confidence** in the company’s ability to: - Scale commercial NO devices meaningfully, and/or - Turn pipeline assets into cash flows before running out of capital. - At the same time, the platform nature (NO across multiple indications) means **any major positive clinical/commercial news can re-rate the stock rapidly**, which you can see in today’s one-day +145% move. So this is **not** a “steady compounding at fair value” situation; it’s **a speculative biotech/medtech option** on the NO platform working out. --- #### What’s been happening recently? **Key recent news (from your data):** | Date | Event | Impact & read-through | |------------|---------------------------------------------------|------------------------| | 2025-11-26 | CFO resignation and search for successor | Generally a mild negative/uncertainty signal: CFO transitions in tiny, loss-making companies can reflect strategic or financing tensions, but can also be just career moves. Worth watching how quickly they appoint a strong replacement and whether there are changes to capital-raising plans. | **Earnings vs expectations (last 4 quarters):** | Quarter (FY) | EPS estimate | EPS actual | Surprise (%) | Interpretation | |--------------|-------------:|-----------:|------------------|----------------| | 2025-09-30 | -0.8721 | -1.25 | **-43.3% miss** | Bigger loss than expected → negative. | | 2025-06-30 | -1.4280 | -1.53 | **-7.1% miss** | Slightly worse than expected. | | 2025-03-31 | -2.4888 | -1.80 | **+27.7% beat** | Loss narrower than expected. | | 2024-12-31 | -3.2640 | -3.00 | **+8.1% beat** | Slight beat, but still deep losses. | Trend: after two quarters of beats as losses narrowed, the last two quarters **missed expectations**, with the latest being a **big miss**, which may have hurt investor confidence. --- ### 3. Deeper Dive (for when you want the full picture) #### 1) Profitability trends (where data is missing, we mark it) | Metric | Latest (TTM) | 1 year ago | 2 years ago | 3-year trend | |------------|--------------|-----------|------------|--------------| | Gross margin | **-6.7%** | [n/a] | [n/a] | [data not provided] | | Net margin | **-632.5%**| [n/a] | [n/a] | [data not provided] | | ROE | **-272.4%**| [n/a] | [n/a] | [data not provided] | Takeaway: even without a time series, the latest numbers are “red flag” enough: **very high losses relative to sales and equity**. --- #### 2) Growth trends | Metric | Latest | 1 year ago | 2 years ago | 3-year trend | |-----------------|------------:|-----------:|------------:|--------------| | Revenue growth | [n/a YoY] | [n/a] | [n/a] | 3Y CAGR **+62.1%**, 5Y CAGR **-13.7%** | | EPS growth | [n/a YoY] | [n/a] | [n/a] | 3Y and 5Y EPS growth: [data not provided] | Interpretation: - Revenue is **growing strongly vs three years ago**, but from a **very low base** and after earlier declines. - EPS remains negative but **the absolute loss per share is narrowing** based on the last 4 quarters. --- #### 3) Quarterly performance vs expectations Already summarized above, but the pattern matters: - **2024-12 & 2025-03:** Narrowing losses, beating expectations → optimism. - **2025-06 & 2025-09:** Losses still narrowing in absolute terms, but **worse than analysts expected**, especially 2025-09 → may have **reset sentiment lower**. For an early-stage name, **trust in management guidance and capital planning** is almost as important as raw EPS. --- #### 4) How does the market view it? **Analyst recommendations (latest period: 2026-01-01):** Total covering analysts: **11** | Rating | Count | Share of total | |--------------|------:|---------------:| | Strong Buy | 2 | ~18% | | Buy | 7 | ~64% | | Hold | 2 | ~18% | | Sell | 0 | 0% | | Strong Sell | 0 | 0% | Analysts overall lean **positive (Buy-biased)** despite the tiny size and big losses. That usually means: - They **like the technology / pipeline potential**. - They are **willing to look through current losses**, assuming financing is manageable. **Target prices:** Not included in your data → **[data not provided]**. So we **cannot** quantify upside/downside to consensus target. --- #### 5) Insider activity From your data: - 2026-01-05: **Daniel J. Moorhead** – +70,000 shares (Code “A” – typically award/grant, not open-market buy). - 2025-11-04: multiple transactions for **Yoori Lee**, with a pattern of awards (“A”) and corresponding disposals (“D”) on the same day, likely related to vesting/settlement of equity compensation. Net effect around a small positive position, but **no clear sign of big open-market buying**. Key point: - The **net recent insider flow is mildly positive** (more awards than disposals), - But these look like **compensation-related**, not strong “I’m putting my own cash in” signals. We also don’t have dollar values → **[data not provided]** for transaction value. --- #### 6) Key risks to keep in mind 1. **Funding & dilution risk** - With **net margin -633%**, **ROE -272%**, and **cash flow per share -2.15**, the business is not self-sustaining. - If commercial traction is slower than hoped, they will almost certainly need **equity raises or dilutive financing**, which can hurt existing shareholders. 2. **Execution and clinical/commercial risk on the NO platform** - The whole thesis rests on **turning nitric oxide technology into scalable, reimbursable products**. - Regulatory setbacks, weaker‑than‑expected clinical data, or slow adoption by hospitals/physicians could materially impact the story and valuation. 3. **Micro-cap and liquidity risk (including potential listing risk)** - With a market cap around **$7.5m**, this is a **very small, likely thinly traded stock**. - That means: - Large bid–ask spreads and high volatility around news. - Potential risk of **Nasdaq non-compliance** (e.g., price thresholds) if the price falls again, which could eventually lead to reverse splits or even down‑listing if not addressed. --- ### Summary & What to Watch **Three-sentence wrap-up** - **What it is:** a micro‑cap, early commercial stage medical device/biopharma company focused on nitric oxide, still solidly in “cash burn” mode. - **Main upside:** strong 3‑year revenue growth, a differentiated technology angle, and generally bullish analyst coverage suggest **real upside** if the NO platform scales and financing is managed well. - **Main downside:** profitability is extremely weak, the company is dependent on external capital, and as a tiny NASDAQ micro‑cap, the stock carries **high dilution and volatility risk**. --- **If you want to dig further from here:** - Curious whether there’s a real **moat** around their NO technology and IP? → Use a “Buffett Mode” style dive into products, patents, and competitors. - Worried about hidden problems (regulatory, trial data, lawsuits, going‑concern warnings)? → A “Muddy Mode” deep risk scan would be useful. - Thinking of it as a **speculative growth bet** and want to know if the risk/reward is worth it at ~$2? → A “Musk Mode” style scenario analysis (commercial success vs. dilution vs. failure) would help quantify that.